Skip to main content
SpringerLink
Log in

Combination chemotherapy of advanced medullary and differentiated thyroid cancer

Phase II study

  • Rapid Communication
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Summary

A group of 20 patients with advanced medullary (MTC) or differentiated thyroid carcinoma (DTC) received a combination chemotherapy of doxorubicin (50 mg/m2), cisplatin (60 mg/m2) and vindesine (3 mg/m2). In the 18 (10 MTC, 8 DTC) evaluable patients only 1 partial remission (in a patient with MTC) and 3 minor responses (in 3 patients with DTC) were observed. These responses lasted for 15, 9, 13, and 22 months, respectively. Three MTC patients suffered from progressive disease and “no change” was seen in the other 11 patients. Toxicity, including 1 severe case of cardiomyopathy, was considerable. Thus, the combination chemotherapy of doxorubicin, cisplatin and vindesine has failed to prove superior to the commonly applied doxorubicin monotherapy in patients with advanced medullary or differentiated thyroid carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

MTC, DTC:

medullary and differentiated thyroid carcinoma

References

  • Ahuja S, Ernst H (1987) Chemotherapy of thyroid carcinoma. J Endocrinol Invest 10:303–310

    Google Scholar 

  • Athanassiades P, Piperingos G, Pandos P, Koutras D, Moulopoulos S (1988) Serial serum calcitonin concentrations to evaluate response to therapy of patients with medullary thyroid carcinoma. Chemioterapia 7:195–197

    Google Scholar 

  • Benker G, Reinwein D (1983) Ergebnisse der Chemotherapie des Schilddrüsenkarzinoms. Dtsch Med Wochenschr 108:403–406

    Google Scholar 

  • Bukowski RM, Brown L, Weick JK (1983) Combination chemotherapy of metastatic thyroid cancer. Phase II study. Am J Clin Oncol (CCT) 6:579–581

    Google Scholar 

  • Droz JP, Schlumberger M, Rougier P, Caillou B, Godefroy W, Gardet P, Parmentier C (1985) Phase II trials of chemotherapy with adriamycin, cisplatin and their combination in thyroid cancers — a review of 44 cases. In: Jaffiol C, Milhaud G (eds) Thyroid cancer. Elsevier Science Publishers, Amsterdam, pp 203–208

    Google Scholar 

  • Gottlieb JA, Hill CS Jr (1974) Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients. N Engl J Med 290:193–197

    Google Scholar 

  • Hedinger C, Williams ED, Sobin LH (1988) Histological typing of thyroid tumours, 2nd edn (International histological classification of tumours No. 11). Springer, Berlin Heidelberg New York

    Google Scholar 

  • Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207–214

    Google Scholar 

  • Petursson SR (1988) Metastatic medullary thyroid carcinoma. Complete response to combination chemotherapy with decarbazine and 5-fluorouracil. Cancer 62:1899–1903

    Google Scholar 

  • Poster DS, Bruno S, Penta J, Pina K, Catane R (1981) Current status of chemotherapy in the treatment of advanced carcinoma of the thyroid gland. Cancer Clin Trials 4:301–307

    Google Scholar 

  • Raue F, Minne H, Ziegler R (1985) Cisplatin, Adriamycin und Vindesin: Eine Kombinationschemotherapie beim differenzierten Schilddrüsenkarzinom. Tumor, Diagn Ther 6:134–138

    Google Scholar 

  • Samaan NA, Schultz PN, Haynie TP, Ordonez NG (1985) Pulmonary metastasis of differentiated thyroid carcinoma: treatment results in 101 patients. J Clin Endocrinol Metab 65:376–380

    Google Scholar 

  • Shimaoka K (1980) Adjunctive management of thyroid cancer: chemotherapy. J Surg Oncol 15:283–286

    Google Scholar 

  • Shimaoka K, Schoenfeld DA, DeWys WD, Creech RH, DeConti R (1985) A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56:2155–2160

    Google Scholar 

  • Tisell LE, Hansson G, Jansson S, Salander H (1986) Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma. Surgery 99:60–66

    Google Scholar 

  • Williams SD, Birch R, Einhorn LH (1986) Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: a southeastern cancer study group trial. Cancer Treat Rep 70:405–407

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine I, University of Heidelberg, D-6900, Heidelberg, Federal Republic of Germany

    Hans Scherübl, Friedhelm Raue & Reinhard Ziegler

Authors
  1. Hans Scherübl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Friedhelm Raue
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Reinhard Ziegler
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

This study was supported by a grant of the German Cancer Research Center (Tumorzentrum Heidelberg/Mannheim)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Scherübl, H., Raue, F. & Ziegler, R. Combination chemotherapy of advanced medullary and differentiated thyroid cancer. J Cancer Res Clin Oncol 116, 21–23 (1990). https://doi.org/10.1007/BF01612635

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01612635

Key words

Search

Navigation